NCT02998879View on ClinicalTrials.gov

Trial on Safety and Efficacy of Velmanase Alfa Treatment in Pediatric Patients With Alpha-Mannosidosis

PHASE2CompletedINTERVENTIONAL
Enrollment

5

Participants

Timeline

Start Date

December 31, 2016

Primary Completion Date

July 31, 2020

Study Completion Date

July 31, 2020

Conditions
Alpha-Mannosidosis
Interventions
DRUG

Velmanase Alfa (e.g. Lamazym)

iv infusion treatment

Trial Locations (6)

Unknown

Vienna

Copenhagen

Lyon

Hamburg

Mainz

Trieste

Sponsors

Collaborators (1)

Cromsource
All Listed Sponsors
collaborator

Cromsource

INDUSTRY

lead

Chiesi Farmaceutici S.p.A.

INDUSTRY

NCT02998879 - Trial on Safety and Efficacy of Velmanase Alfa Treatment in Pediatric Patients With Alpha-Mannosidosis | Biotech Hunter | Biotech Hunter